Garrison, L, Towse, A, Briggs, A, et al.
Performance-based rish sharing arrangements - Good practices for design, implementation, and evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force.
Value Health. 2013;16: 703–719.
Klemp, M, Fronsdal, K, Facey, K. What principles should govern the use of managed entry agreements?
Int J Technol Assess Health Care. 2011;27:77–83.
Australian Government. PBAC Guidelines for submissions: Commonwealth of Australia. http://www.pbac.pbs.gov.au/ (accessed November 22, 2017).
Carlson, JJ, Garrison, LP Jr, Sullivan, SD. Paying for outcomes: Innovative coverage and reimursement schemes for pharmaceuticals. J Manag Care Pharm. 2009;15:683–687.
Carlson, J, Sullivan, S, Garrison, L, Neumann, P, Veenstra, D. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. J Health Policy. 2010;96:179–190.
Towse, A, Garrison, L. Can't get no satisfaction: Will pay for permformance help?
Makino, K, Tilden, D, Kamei, M, Shibata, K. Risk-Sharing agreements in Australia: Attitude towards risk-sharing arrangements with the Department of Health for the PBS listing of pharmaceuticals. Value Health. 2014;17:A801.
Ferrario, A, Kanavos, P. Dealing with uncertainty and high prices of new medicines; A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Soc Sci Med. 2015;124:39–47.
Jaroslawski, S, Toumi, M. Market access agreements for pharmaceuticals in Europe: Diversity of approaches and underlying concepts. BMC Health Serv Res. 2011;11:259–266.
Walker, S, Sculpher, M, Claxton, K, Palmer, S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15:570–579.
McCabe, C, Stafinski, T, Edlin, R, Menon, D. Access with evience development schemes: A framework for descriptions and evaluation. Pharmacoeconomics. 2010;28:143–152.
Coulton, L, Annemans, L, Javier, J, Brown, R, Keskinaslan, A, eds. Risk-sharing schemes worldwide: A landscape analysis of health outcomes-based reimbursement agreements. ISPOR 4th Asia-Pacific Conference; 2010; Phuket, Thailand.
Vitry, A, Roughead, E. Managed entry agreements for pharmaceuticals in Australia.
Health Policy. 2014;117:345–452.
Lu, C, Lupton, C, Ralowsky, S, Babar, Z-U-D, Ross-Degnan, D, Wagner, A. Patient access schemes in Asia-pacific markets:current experience and future potential. J Pharm Policy Pract. 2015;8:6.
Robertson, J, Walkom, E, Henry, D. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
Aust Health Rev. 2009;33:192–199.
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Methodology [updated December 15, 2016]. https://www.whocc.no (accessed November 22, 2017).
Drummond, M, Sculpher, M, Torrance, G, O'Brien, B, Stoddart, G. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.
Toumi, M, Jaroslawski, S. Patient access schemes in UK are driven by health technology assessment. Value Health. 2011;13:A246.
Toumi, M, Jaroslawski, S, Sawada, T, Kornfeld, A. The use of surrogate and patient-relevant endpoints in outcomes-based market access agreements: Current debate. Applied Health Econ Health Policy. 2017;15:5–11.
Fagnani, F, Pham, T, Claudepierre, P, et al.
Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France.
J Med Econ. 2016;19:812–821.
Jaroslawski, S, Toumi, M. Design of patient access schemes in the UK.
Appl Health Econ Health Policy. 2011;9:209–215.
Lu, C, Williams, K, March, L, Sansom, L, Bertouch, J. Access to high cost drugs in Australia.
Espin, J, Rovira, J, Garcia, L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. Granada, Spain: Andalusian School of Public Health; 2011.
Edmonds, D, Dumbrell, D, Primrose, J, Birkett, D, Demirian, V. Development of an Australian Drug Utilization Database: A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.
Briggs, A, Ritchie, K, Fenwick, E, Chalkidou, K, Littlejohn, P. Access with evidence development in the UK: Past experience, current initiatives and future potential. Pharmacoeconomics. 2010;28:163–170.
van de Vooren, K, Curto, A, Freemantle, N, Garattini, L. Market-access agreements for anti-cancer drugs. J R Soc Med. 2015;108:166–170.
Williamson, S. Patient access schemes for high-cost cancer medicines. Lancet Oncol. 2010;11:111–112.
Conter H. Financial risk-sharing agreements: Using options to make marginal benefits cost effective. J Clin Oncol. 2016;34
Garrison, L, Carlson, J, Bajaj, P, et al.
Private sector risk-sharing agreements in the United States: Trends, barriers and prospects. Am J Manag Care. 2015;21:632–640.
Maguire, P, Gibson, E. Patient access schemes within the UK: A retrospective analysis. Value Health. 2015;18:A335–A766.
Tettamanti, A, Urbinati, D, Noble, M. Market access entry agreements in the Italian market between January 2006 and April 2015. Value Health. 2015;18:A334–A766.
Atkinson, W. The impact of CED on private payers. Biotechnol Healthc. 2007;4:24–30.
Lu, C, Williams, K, Day, R. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target?
Intern Med J. 2006;36: 19–27.
Garattini, L, Curto, A, van de Vooren, K. Italian risk-sharing agreements on drugs: Are they worthwhile?
Eur J Health Econ. 2015;16:1–3.
Bishop, D, Lexchin, J. Politics and its intersection with coverage with evidence development: A qualitative anlaysis from expert interviews. BMC Health Serv Res. 2013;13:88–98.